SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Serina Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates

Independent Safety Monitoring Committee recommended advancement of SER-252 in Parkinson's disease

SER

Related stories